Benjamin J. Hindson - 22 Mar 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
President and Chief Scientific Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Benjamin J. Hindson
Issuer symbol
TXG
Transactions as of
22 Mar 2022
Net transactions value
$0
Form type
4
Filing time
24 Mar 2022, 17:17:03 UTC
Previous filing
24 Feb 2022
Next filing
25 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Award $0 +28,476 +18% $0.000000 188,802 22 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (Right to Buy) Award $0 +71,189 $0.000000 71,189 22 Mar 2022 Class A Common Stock 71,189 $69.56 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2 This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

President and Chief Scientific Officer